Boehringer Ingelheim Pharma
Boehringer Ingelheim Pharma
1 Projects, page 1 of 1
assignment_turned_in Project2019 - 2027Partners:European Synch Radiation Facility - ESRF, Helmholtz Association, Centre for Process Innovation (Dup'e), NanoTemper, Reprocell-Europe +47 partnersEuropean Synch Radiation Facility - ESRF,Helmholtz Association,Centre for Process Innovation (Dup'e),NanoTemper,Reprocell-Europe,Astex,Concept Life Sciences (United Kingdom),Max iv,Cambridge Crystallographic Data Centre,South Tees Hospitals NHS Foundtn Trust,Reprocell-Europe,NanoTemper,Universidade de Sao Paulo,CRB,Bruker Daltonik GmbH,Bionow Ltd,CPI Ltd,Newcastle University,LightOx Ltd,Bruker Daltonik GmbH,European Synch Radiation Facility - ESRF,Boehringer Ingelheim Pharma,Newcastle University,Diamond Light Source,High Force Research Ltd,Bionow Ltd,South Tees Hospitals NHS Foundtn Trust,University of Sao Paolo,Diamond Light Source,University of Sao Paulo,GlaxoSmithKline (Harlow),Cambridge Research Biochemicals,High Force Research Ltd,Centre for Process Innovation,Darlington,Max iv,LightOx Ltd,Helmholtz Association of German Research Centres,Arc Trinova Ltd (Arcinova),ALMAC SCIENCES,Glythera Ltd,GlaxoSmithKline PLC,Lund University,Boehringer Ingelheim (International),Concept Life Sciences,Arcinova,Boehringer Ingelheim Pharma,Concept Life Sciences,Almac Group Ltd,CCDC,GSK,Astex,GlytheraFunder: UK Research and Innovation Project Code: EP/S022791/1Funder Contribution: 7,571,970 GBPMolecular sciences, such as chemistry, biophysics, molecular biology and protein science, are vital to innovations in medicine and the discovery of new medicines and diagnostics. As well as making a crucial contribution to health and society, industries in this field provide an essential component to the economy and contribute hugely to employment figures, currently generating nearly 500,000 jobs nationally. To enable and facilitate future economic growth in this area, the CDT will provide a cohort of researchers who have training in both aspects of this interface who will be equipped to become the future innovators and leaders in their field. All projects will be based in both molecular and medical sciences and will focus on unmet medical needs, such as understanding of disease biology, identification of new therapeutic targets, and new approaches to discovery and development of novel therapies. Specific problems will be identified by researchers within the CDT, industrial partners, stakeholders and the CDT students. The research will be structured around three theme areas: Biology of Disease, Molecule and Assay Design and Structural Biology and Computation. The CDT brings together leading researchers with a proven track record across these areas and who have pioneered recent advances in the field, such as multiple approved cancer treatments. Their combined expertise will provide supervision and mentorship to the student cohort who will work on projects that span these research themes and bring their contributions to bear on the medical problems in question. The student cohort approach will allow teams of researchers to work together on joint projects with common goals. Projects will be proposed between academics, industrial partners and students with priority given to those with industrial relevance. The programme of research and training across the disciplines will equip graduates of the CDT with an unprecedented background of knowledge and skills across the disciplines. The programme of research and training across the disciplines will be supplemented by training and hands-on experiences of entrepreneurship, responsible innovation and project management. Taken together this will make graduates of the CDT highly desirable to employers, equip them with the skills they need to envisage and implement future innovations in the area and allow them to become the leaders of tomorrow. A structured and highly experienced management group, consisting of a director, co-directors, theme leads and training coordinators will oversee the execution of the CDT with the full involvement of industry partners and students. This will ensure delivery of the cohort training programme and joint events as well as being accountable for the process of selection of projects and student recruitment. The management team has an established track record of delivery of research and training in the field across industry and academia as well as scientific leadership and network training coordination. The CDT will be delivered as a single, fully integrated programme between Newcastle and Durham Universities, bringing together highly complementary skills and backgrounds from the two institutions. The seamless delivery of the programme across the two institutions is enabled by their unique connectivity with efficient transport links and established regional networks. The concept and structure of the CDT has been developed in conjunction with the industrial partners across the pharmaceutical, biotech and contract research industries, who have given vital steer on the desirability and training need for a CDT in this area as well as to the nature of the theme areas and focus of research. EPSRC funding for the CDT will be supplemented by substantial contributions from both Universities with resources and studentship funding and from industry partners who will provide training, in kind contribution and placements as well as additional studentships.
more_vert
